SABCS 2022 Phase 3 DESTINY-Breast02 Study: T-DXd Efficacy in Patients With HER2+ Unresectable/mBC Previously Treated With T-DM1

By ecancer FEATURING Ian Krop
By ecancer FEATURING Ian Krop
99 views
January 10, 2023
Comments 0
Login to view comments. Click here to Login